Share on StockTwits

GenMark Diagnostics (NASDAQ:GNMK) SVP Jon Faiz Kayyem unloaded 1,483 shares of the company’s stock on the open market in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $10.69, for a total value of $15,853.27. Following the completion of the transaction, the senior vice president now directly owns 109,981 shares of the company’s stock, valued at approximately $1,175,697. The sale was disclosed in a legal filing with the SEC, which is available at this link.

A number of research firms have recently commented on GNMK. Analysts at Raymond James reiterated an “outperform” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $11.00 price target on the stock, down previously from $14.00. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $16.00 price target on the stock, down previously from $17.00. Finally, analysts at Cowen and Company reiterated an “outperform” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $15.00 price target on the stock, down previously from $16.00. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $15.00.

Shares of GenMark Diagnostics (NASDAQ:GNMK) traded up 2.85% during mid-day trading on Thursday, hitting $10.81. The stock had a trading volume of 224,311 shares. GenMark Diagnostics has a 52 week low of $8.48 and a 52 week high of $15.16. The stock’s 50-day moving average is $9.51 and its 200-day moving average is $11.38. The company’s market cap is $449.8 million.

GenMark Diagnostics (NASDAQ:GNMK) last announced its earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.04. The company had revenue of $7.91 million for the quarter, compared to the consensus estimate of $6.40 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. The company’s revenue for the quarter was down 28.7% on a year-over-year basis. Analysts expect that GenMark Diagnostics will post $-1.15 EPS for the current fiscal year.

GenMark Diagnostics, Inc (NASDAQ:GNMK) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.